$IMLFF InMed is initially targeting Epidermolysis Bullosa (EB) and Glaucoma with specific cannabinoid compounds that have shown promise in early studies. EB is an orphan condition that has no currently approved treatments, which could pave the way for faster regulatory approvals and a dramatic improvement in patient quality of life. Glaucoma is the second leading cause of blindness in the developed world.

https://finance.yahoo.com/news/inmed-pharma-c...00706.html

$VBIO $GWPH $AXIM